King Faisal Specialist Hospital & Research Centre

RIYADH, SAUDI ARABIA, January 24, 2026 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSHRC) has inked a memorandum of understanding with Servier Saudi Arabia Trading Company to collaborate on scientific and clinical initiatives related to rare diseases, including glioma which is an area of significant unmet medical need in the region, particularly affecting patients in their 30s and 40s. The partnership will cover research, digital health innovation, medical education, and scientific exchange. Signed at KFSHRC’s headquarters in Riyadh, the MoU sets a framework for joint work in areas of mutual interest. It aims to strengthen specialized knowledge in glioma and related oncology fields in Saudi Arabia, explore opportunities to generate insights from clinical practice, and assess potential digital health innovations, subject to the relevant regulatory requirements for any future initiatives. The collaboration also includes scientific exchange and medical education through conferences, seminars, workshops, and related training activities, alongside initiatives to raise awareness and build capabilities in precision medicine and related genomic testing. The MoU supports the Kingdom’s healthcare transformation under Saudi Vision 2030 by advancing specialized care models and strengthening scientific and research collaboration, including in the field of rare diseases. KFSHRC ranks first in the Middle East and Africa and fifteenth globally among the world’s top 250 academic medical centers for 2025. It also holds the highest valued healthcare brand in Saudi Arabia and the region, according to Brand Finance 2024, and is listed by Newsweek among the World’s Best Hospitals 2025, the World’s Best Smart Hospitals 2026, and the World’s Best Specialized Hospitals 2026. “Servier is an independent international pharmaceutical company governed by a nonprofit foundation, with a clear commitment to social impact, patient benefit, and long-term sustainability. A global leader in hypertension and venous diseases and a major player in cardiometabolism. Servier’s ambition is to become a leading player in rare cancers through precision medicine and invests nearly 70% of its R&D budget in oncology. Riyadh KFSHRC email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

RIYADH, SAUDI ARABIA, December 31, 2025 / EINPresswire.com / -- King Faisal Specialist Hospital & Research Centre continues to play a leading regional role in pediatric stem cell transplantation through a highly specialized program serving children with malignant and non-malignant diseases, inherited blood disorders, immunodeficiencies, and metabolic conditions. The Pediatric Stem Cell Transplant Program performs approximately 130 transplants annually for patients from birth to under 14 years of age, following internationally accredited clinical and quality standards to ensure patient safety, donor protection, and product integrity. To expand access to transplantation, the program has developed a robust alternative donor strategy that includes partially matched, haploidentical, and unrelated donors. This expansion has increased treatment opportunities for patients without fully matched donors and reflects the program’s growing clinical and organizational maturity. A dedicated transplant data center maintains comprehensive records of all transplant cases dating back to 1993, covering more than 2,900 patients. These data support long-term follow-up, continuous outcome evaluation, and benchmarking against international reference centers. Education and research are integral to the program’s mission. Through structured fellowship training and active research participation, the program contributes to advancing clinical practice and knowledge exchange in stem cell transplantation and pediatric hematologic malignancies. KFSHRC ranks first in the Middle East and Africa and fifteenth globally among the world’s top 250 academic medical centers for 2025. It also holds the highest valued healthcare brand in Saudi Arabia and the region, according to Brand Finance 2024, and is listed by Newsweek among the World’s Best Hospitals 2025, the World’s Best Smart Hospitals 2026, and the World’s Best Specialized Hospitals 2026. Riyadh KFSHRC email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

JEDDAH, SAUDI ARABIA, December 31, 2025 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Jeddah has manufactured and introduced a post-transplant booster dose for bone marrow transplant patients, an advanced cellular immunotherapy designed to support transplant success and reduce the risk of relapse. The milestone is a first for the Western Region’s healthcare sector, giving patients quicker, safer access to specialized follow-up care while sparing them the physical, financial, and emotional strain of travel during recovery. The development targets a long-standing gap in post-transplant care. Clinical data show relapse after bone marrow transplantation can reach roughly one-third in some cases, highlighting the need for precisely timed supportive interventions after the procedure. Until now, patients often had to travel to Riyadh or outside the Kingdom to receive this type of therapy. With the service now available in Jeddah, patients can receive critical post-transplant support closer to home. The booster dose is delivered intravenously during a short visit, without the need for prolonged hospitalization. It is prepared from healthy cells collected in advance from the original donor before the transplant, then returned to the patient in carefully measured doses to reinforce engraftment and strengthen the body’s ability to prevent disease recurrence. The approach boosts immunity, improves clinical stability, and reduces the likelihood of relapse over the longer term. The therapy's human impact was evident in its first recipient, a patient from Jeddah who had undergone a bone marrow transplant and was at risk of relapse. He received the booster dose at the right time in his home city, surrounded by family, sparing him from traveling during a critical phase when he needed stability and close-to-home care most. The achievement strengthens KFSHRC Jeddah’s capacity to deliver precision cellular therapies and expand the use of advanced immunotherapies, reinforcing its role in developing care for blood disorders and bone marrow transplantation. It also supports the hospital’s vision of being the provider of choice for every patient. KFSHRC has been ranked first in the Middle East and North Africa and fifteenth globally among the world’s top 250 academic medical centers for 2025 and recognized by Brand Finance as the region’s most valuable healthcare brand. It is also listed among Newsweek’s World’s Best Hospitals 2025, Best Smart Hospitals 2026, and Best Specialized Hospitals 2026, reaffirming its leadership in innovation-driven care. Jeddah KFSHRC email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.